MARKET WIREYahoo Finance • 12h ago
DexCom (DXCM) Stock Looks Below Fair Value on Cash FlowYahoo Finance report covering DexCom Inc. (DXCM) market action, institutional positioning, and fundamental catalysts.
Why DXCM Stock surged +2.95% Today — RQD Quant Desk Flash
$82.29 +2.95% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $82.92
DexCom Inc. (DXCM) earns a Roarable Rating of B+ (Buy) with 76/100 RQD Confidence. High-quality cash engine (60% profit margin, 22% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
ROARABLE B+ • BUY
Cap $30.16B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on DXCM Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is DXCM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, DexCom Inc. (NASDAQ: DXCM) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 76/100 at a spot price of $82.29 (+2.95% 1D, market cap $30.16B). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 16/20. Across 1016 tracked Health Care issuers, DXCM ranks #32 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does DXCM compare to WST and RMD in the Health Care sector?
▼
Within the Health Care sector (Medical/Dental Instruments), DXCM carries a Roarable B+ (76/100 RQD), trailing P/E of 36.1x, gross margin of 60.1%, and ROIC of 21.6%. By comparison, WST (West Pharmaceutical Services Inc.) holds a A- grade (81/100 RQD, P/E 59.4x, ROIC 17.9%, cap $29.32B) and RMD (ResMed Inc.) posts a A grade (86/100 RQD, P/E 25.4x, ROIC 22.9%, cap $35.56B). Among the 5-stock peer group, RMD leads on earnings multiple (25.4x) while RMD leads on capital efficiency (22.9% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for DXCM?
▼
Per DXCM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001093557), DexCom Inc. generated $4.66B in revenue (+15.6% YoY), $836.3M in net income, and $1.08B in free cash flow against $6.34B in total assets and $1.62B in total debt. Key quantitative strengths: Strong cash generator (60% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $82.92 (+0.77%)🧬 Cannibal Buyback (-2.36% YoY Shares)⚙️ Cash Engine: 19/20 (A+) • 23.1% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 76/100 (B+) historically ranked in the Top 11% of excess returns over the next 90 days (+7.6% avg 90D alpha vs SPY • 70.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERBUY • B+
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw B · Rk B+
Each axis scored 0–20
12M PRICE TARGET CONE+8.1% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DXCM)Realized 20D OHLCV Swing Band: ±6.4%
Deterministic 5-Pillar Attribution (76/100 Composite)
🔍 WHY DXCM SCORES 76/100 (B+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+19/20 pts (25% of score)
SEC XBRL FY 2025 (10-K): 23.1% FCF Margin ($1.08B FCF) & 60.1% Gross Margin
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (24% of score)
Altman Z-Score 7.14 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9
▼ #1 Drag / Risk Factor: Whale & Options Positioning10/20 pts (-10 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-10 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade A$85.06+0.8% Next Q
84
Q2 (-2Q)Grade A-$85.74-8.4% Next Q
81
Q3 (-1Q)Grade A-$78.56+4.7% Next Q
79
CurrentGrade B+$82.29+7.6% Hist 90D α
76
Trajectory: A (84) → B+ (76)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the DXCM Bull Thesis Could Fail
Even with a 76/100 (B+) score, DXCM faces multiple-compression risk if 36.1x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Broader market pullbacks can still drag down strong stocks in the short run.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-2.36% YoY Shares) — any gross margin slip below 57.6% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($85.35) or 200D SMA ($74.67) invalidates the momentum regime and cuts Target Base ($88.96) toward Bear Floor ($67.48).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $DXCM• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “DXCM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why DXCM Stock surged +2.95% Today — RQD Quant Desk Flash
DexCom Inc. (DXCM) surged +2.95% to $82.29, trading at 73% of its 52-week range ($54.11 – $92.59). High-quality cash engine (60% profit margin, 22% return on capital) with steady institutional support.
- ▸Technical Tape: Trading at 73% of its 52-week range ($54.11 – $92.59) with RSI-14 at 41.8 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±6.4% around $82.29 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable B+ (Buy) backed by 60.1% gross margin and $1.1B annual free cash flow.
Live DXCM Headlines & Catalysts
CATALYSTGuruFocus • 15h ago
DexCom (DXCM) Shares Fall 6.5% Amid Broader Market Gains on OctoGuruFocus report covering DexCom Inc. (DXCM) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 18h ago
Here's Why You Should Retain DexCom Stock in Your Portfolio for NowYahoo Finance report covering DexCom Inc. (DXCM) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESeeking Alpha • 21h ago
DexCom: Improving Patient Access Makes It A Long-Term Buy (NASDAQ:DXCM)Seeking Alpha report covering DexCom Inc. (DXCM) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 1d ago
Here’s How Much You Would Have Made Owning DexCom Stock In The Last 15 YearsBenzinga report covering DexCom Inc. (DXCM) market action, institutional positioning, and fundamental catalysts.
MARKET WIREmarketscreener.com • 1d ago
Earnings Flash (DXCM) DexCom, Inc. Posts Q3 Adjusted EPS $0.73 per Share, vs. FactSet Est of $0.67marketscreener.com report covering DexCom Inc. (DXCM) market action, institutional positioning, and fundamental catalysts.
RISK WATCHQuiver Quantitative • 1d ago
DexCom Falls as Investors Appear to Take Profits Ahead of Earnings | DXCM Stock NewsQuiver Quantitative report covering DexCom Inc. (DXCM) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
DexCom (DXCM) Stock Could Be 41% Undervalued As Guidance RisesSimply Wall St report covering DexCom Inc. (DXCM) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo • 11h ago
Abbott, Dexcom grapple with diabetes coverage ahead of planned Medicare expansionAbbott said it is facing pricing pressure and slower growth ahead of a planned coverage expansion for people with Type 2 diabetes. Competitor Dexcom, however, did not experience the same slowdown.
MARKET WIREYahoo • 14h ago
Dexcom Invites the Global Diabetes Community to Share Their Stories Through A Letter to Diabetes CampaignSAN DIEGO, November 02, 2026--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today launched A Letter to Diabetes in honor of National Diabetes Awareness Month and World Diabetes Day, creating a pla
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (DXCM Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
DXCM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +37.06%📐 WEDGE COMPRESSION COIL
2026-11-02O $78.62H $82.29L $78.62C $82.29VOL 5.92M
RES: $87.70SUP: $77.19SMA50: $85.35SMA200: $74.67
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
DXCM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
27.8%/yr Implied 5Y Growth
vs. +15.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on DXCM today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
LLY → DXCM Analyst Hypothesis
Real-world payer claims data show clinicians co-prescribe Dexcom G7 and OTC Stelo continuous glucose monitors (CGMs) alongside GLP-1 initiation for metabolic feedback, offsetting delayed progression to basal insulin.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for DXCM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DXCM)
Health Care Rank #32 of 1016
⚔️ WST vs DXCM Full Matrix →
1. Head-to-Head Health Care Peer Comparison (DXCM vs. WST, RMD, MDLN, BDX)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, DexCom Inc. (DXCM) ranks #32 by composite RQD confidence (76/100, grade B+) and #57 by equity capitalization ($30.16B). Within this direct 5-issuer industry benchmark cohort, RMD leads on earnings valuation at 25.4x trailing P/E, while RMD leads on capital efficiency and profitability with 22.9% ROIC and 59.4% gross margin. RMD currently holds the highest overall quantitative score in the immediate peer group at 86/100 (A) compared with DXCM at 76/100 (B+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| DXCM
ACTIVE
DexCom Inc. | B+ | 76/100 | 36.1x | 60.1% | 21.6% | +2.95% | $30.16B | Benchmark Subject |
| WST West Pharmaceutical Services Inc. | A- | 81/100 | 59.4x | 35.9% | 17.9% | -0.97% | $29.32B | /wst-vs-dxcm → |
| RMD ResMed Inc. | A | 86/100 | 25.4x | 59.4% | 22.9% | -9.05% | $35.56B | /rmd-vs-dxcm → |
| MDLN Medline Inc. | D | 44/100 | — | — | 8.2% | +0.38% | $42.07B | /mdln-vs-dxcm → |
| BDX Becton Dickinson and Company | C+ | 67/100 | 32.2x | 45.4% | 4.9% | -0.23% | $54.03B | /bdx-vs-dxcm → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001093557In its most recent audited fiscal period (FY2025, filed 2025-12-31), DexCom Inc. (DXCM) reported GAAP revenue of $4.66B (+15.6% vs. FY2024 revenue of $4.03B , and +28.7% cumulative change since FY2023) , GAAP net income of $836.3M, operating cash flow of $1.44B, and free cash flow of $1.08B (+70.8% YoY). On the balance sheet, DXCM closed FY2025 with $6.34B in total assets against $1.62B in total debt (Altman Z-Score: 7.14, Piotroski F-Score: 9/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $4.66B | $836.3M | $1.44B | $1.08B | $6.34B | $1.62B |
| FY2024 (FY) | 2024-12-31 | $4.03B | $576.2M | $989.5M | $630.7M | $6.48B | $1.97B |
| FY2023 (FY) | 2023-12-31 | $3.62B | $541.5M | $748.5M | $585.5M | $16.59B | $3.88B |
3. DXCM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs DXCM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, DexCom Inc. (NASDAQ: DXCM) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 76/100 at a spot price of $82.29 (+2.95% 1D, market cap $30.16B). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 16/20. Across 1016 tracked Health Care issuers, DXCM ranks #32 in composite RQD confidence.
How does DXCM compare to WST and RMD in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), DXCM carries a Roarable B+ (76/100 RQD), trailing P/E of 36.1x, gross margin of 60.1%, and ROIC of 21.6%. By comparison, WST (West Pharmaceutical Services Inc.) holds a A- grade (81/100 RQD, P/E 59.4x, ROIC 17.9%, cap $29.32B) and RMD (ResMed Inc.) posts a A grade (86/100 RQD, P/E 25.4x, ROIC 22.9%, cap $35.56B). Among the 5-stock peer group, RMD leads on earnings multiple (25.4x) while RMD leads on capital efficiency (22.9% ROIC).
What are the biggest fundamental strengths and SEC risk factors for DXCM?
Per DXCM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001093557), DexCom Inc. generated $4.66B in revenue (+15.6% YoY), $836.3M in net income, and $1.08B in free cash flow against $6.34B in total assets and $1.62B in total debt. Key quantitative strengths: Strong cash generator (60% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is DXCM trading relative to its 50-day, 200-day, and 52-week technical levels?
DXCM last traded at $82.29 (+2.95% on volume of 8,638,172 shares), positioning the stock -3.59% below its 50-day simple moving average ($85.35) and +10.20% above its 200-day simple moving average ($74.67). Across its 52-week range of $54.11 to $92.59, DXCM sits at the 73.2% percentile with a 14-day RSI of 41.8 (NEUTRAL RANGE) and an implied next-earnings move of ±6.4% ($77.02 to $87.56).
DXCM Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is DXCM stock moving today?
Why DXCM Stock surged +2.95% Today — RQD Quant Desk Flash. High-quality cash engine (60% profit margin, 22% return on capital) with steady institutional support.
ROARABLE RATING BRIEF • RQD 76/100 (B+)
✓ STAGE-C NUMBER FIREWALL VERIFIED
DXCM — DexCom Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:12:22Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, DXCM scores 76 out of 100 (letter grade B+), labeled "Roarable Buy — Very Good Cash & Smart-Money Inflow." The five pillars are:
- Fundamental Cash Engine: 19 / 20. Per the RQD rating, this reflects ROIC of 21.6% and an FCF yield of 3.57%. For an investor, this is the strongest pillar: returns on invested capital are high relative to the cost of capital, and free cash generation supports the valuation narrative. The FCF yield of 3.57% is modest, however, meaning the stock is not cheap on a cash basis at the current price.
- Whale 13F Flow: 10 / 20. Per the RQD rating, this pillar reflects institutional accumulation and options positioning. It is the weakest pillar, indicating that institutional conviction is only moderate. The holders section contains no 13F detail, so the underlying drivers of this score cannot be verified from the provided sources.
- Insider Conviction: 16 / 20. Per the RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow. The transaction-level detail is not provided in the sources, so the direction and size of insider activity cannot be confirmed here.
- Macro Regime Fit: 13 / 20. Per the RQD rating, beta of 1.1 indicates slightly above-market sensitivity to broad moves. This is a moderate, not defensive, profile, and the score reflects sector sensitivity without a stated macro thesis in the sources.
- Forensic Balance Sheet: 18 / 20. Per the RQD rating, Altman Z of 7.14, Piotroski F of 9/9, and Debt/Equity of 0.55 indicate strong financial health and low distress risk.
Investor implication: the rating points to strong operating economics and balance-sheet quality as the primary support, with smart-money and macro-regime pillars contributing less. Valuation is the main tradeoff: at a P/E (TTM) of 36.1 and EV/EBITDA of 25.2, the market is pricing in substantial future growth, so upside depends on sustained execution. This is an educational summary, not personalized advice.
Snapshot
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $4662.0M | $911.8M | $836.3M | N/A | $1077.2M | $917.7M | $1617.3M |
| FY 2024 | $4033.0M | $600.0M | $576.2M | N/A | $630.7M | $606.1M | $1971.9M |
| FY 2023 | $3622.3M | $597.7M | $541.5M | N/A | $585.5M | N/A | $3881.9M |
Per the SEC financials, revenue grew from $3622.3M (FY 2023) to $4662.0M (FY 2025), and net income rose from $541.5M to $836.3M over the same span. Per the market data, gross margin is 60.1%, operating margin 19.6%, and net margin 17.9%, with ROIC of 21.6%. Per the Roarable RQD rating, the Altman Z-Score is 7.14 and the Piotroski F-Score is 9/9. Debt declined from $3881.9M (FY 2023) to $1617.3M (FY 2025), and per the RQD rating, Debt/Equity is 0.55, consistent with a deleveraged balance sheet.
Recent Catalysts & News Wire Analysis
- Valuation framing (Yahoo Finance headline): A report titled "DexCom (DXCM) Stock Looks Below Fair Value on Cash Flow" appeared, flagged YELLOW.
- Price action (GuruFocus headline): A report titled "DexCom (DXCM) Shares Fall 6.5% Amid Broader Market Gains on Octo" appeared, flagged GREEN as a catalyst. The headline is truncated in the source.
- Long-term thesis (Seeking Alpha): A report titled "DexCom: Improving Patient Access Makes It A Long-Term Buy" appeared, flagged YELLOW.
- Earnings (marketscreener.com): A report titled "Earnings Flash (DXCM) DexCom, Inc. Posts Q3 Adjusted EPS $0.73 per Share, vs. FactSet Est of $0.67" appeared, flagged YELLOW. Per this headline, adjusted EPS of $0.73 exceeded the FactSet estimate of $0.67.
- Butterfly link (GLP-1 ripple): Per the Butterfly Supply-Chain Graph, the link LLY → DXCM is typed BOTTLENECK_BENEFICIARY with an ANALYST_HYPOTHESIS evidence tier and MIXED_CONSTRAINT direction. Per the graph, clinicians reportedly co-prescribe Dexcom G7 and Stelo alongside GLP-1 initiation. The exposure percentage is undisclosed. Next catalyst per the graph: quarterly U.S. sensor volume growth, Stelo OTC run-rate, and non-insulin PBM coverage wins.
- Risk watch: Per the graph, the competing explanation is Abbott FreeStyle Libre price competition and payer restrictions limiting reimbursed CGM coverage to insulin-treated diabetics. The graph also cites lower ASP on OTC Stelo biosensors as a mix pressure.
- Proprietary signals: None provided in the source data.
Open Questions
- What is the undisclosed percentage of revenue tied to GLP-1 companion prescribing, and is it growing?
- What are the specific 13F institutional position changes and options positioning behind the 10/20 whale-flow pillar?
- What is the direction and size of the SEC Form 4 insider and Congressional trades underlying the 16/20 insider pillar?
- What is the FY 2025 EPS, which the financials show as N/A, and how does it reconcile with the TTM EPS of 2.22?
- What is the FY 2023 cash balance, which is N/A, and how has the cash position trended on a full-series basis?
DXCM Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for DexCom Inc. (DXCM) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 12h ago
DexCom (DXCM) Stock Looks Below Fair Value on Cash Flow Yahoo Finance report covering DexCom Inc. (DXCM) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST GuruFocus • 15h ago
DexCom (DXCM) Shares Fall 6.5% Amid Broader Market Gains on Octo GuruFocus report covering DexCom Inc. (DXCM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 18h ago
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now Yahoo Finance report covering DexCom Inc. (DXCM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Seeking Alpha • 21h ago
DexCom: Improving Patient Access Makes It A Long-Term Buy (NASDAQ:DXCM) Seeking Alpha report covering DexCom Inc. (DXCM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 1d ago
Here’s How Much You Would Have Made Owning DexCom Stock In The Last 15 Years Benzinga report covering DexCom Inc. (DXCM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE marketscreener.com • 1d ago
Earnings Flash (DXCM) DexCom, Inc. Posts Q3 Adjusted EPS $0.73 per Share, vs. FactSet Est of $0.67 marketscreener.com report covering DexCom Inc. (DXCM) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Quiver Quantitative • 1d ago
DexCom Falls as Investors Appear to Take Profits Ahead of Earnings | DXCM Stock News Quiver Quantitative report covering DexCom Inc. (DXCM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
DexCom (DXCM) Stock Could Be 41% Undervalued As Guidance Rises Simply Wall St report covering DexCom Inc. (DXCM) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
DXCM Bull vs. Bear Conversation Board — What's Your Call at $82.29?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON DXCM 🐻 33% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH
🎯 Target: $94.32 (+18.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is DXCM (B+ • RQD 76/100) a Buy at $79.93?
Welcome to the DXCM (DexCom Inc.) Roar Pit. Current RQD Composite is 76/100 (Roarable Buy — Very Good Cash & Smart-Money Inflow) in Medical/Dental Instruments. Bulls point to capital efficiency (21.6% ROIC), while bears focus on valuation multiple compression (36.1x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $59.95 (-25.0%)
Spot @ $79.93 Pump the brakes on DXCM — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on DXCM, but look at what you are paying: 36.1x trailing P/E with 60.1% gross margins. Unless DexCom Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH
🎯 Target: $94.32 (+18.0%)
Spot @ $79.93 DXCM cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on DXCM, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $79.93 (52-wk range $54.11 - $92.59), any beat on forward guidance forces shorts and underweight funds to chase.